The biology of preeclampsia

Kidney International

Volumn 76, Issue 8, 2009, Pages 831-837

  Kanasaki, Keizo ^a   Kalluri, Raghu ^a,b,c  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Blood pressure; glomerular endothelial cells; hypoxia; renal pathology

Indexed keywords

2 METHOXYESTRADIOL; CATECHOL METHYLTRANSFERASE; HYPOXIA INDUCIBLE FACTOR;

CELLULAR IMMUNITY; DISEASE MODEL; ENZYME DEFICIENCY; HUMAN; HYPERTENSION; HYPOXIA; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PLACENTA; PREECLAMPSIA; PRIORITY JOURNAL; PROTEINURIA; SHORT SURVEY; TH1 CELL;

ANIMALS; BLOOD PRESSURE; CATECHOL O-METHYLTRANSFERASE; CELL HYPOXIA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KILLER CELLS, NATURAL; MODELS, ANIMAL; PLACENTA; PLACENTAL CIRCULATION; PRE-ECLAMPSIA; PREGNANCY; PROTEINURIA; RISK FACTORS; SIGNAL TRANSDUCTION; TH1 CELLS;

EID: 70349667016     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.284     Document Type: Short Survey

References (61)

1. Martin J, Hamilton B, Sutton P et al. Births: final data for 2006. Natl Vital Stat Rep 2009.
2. Lever JCW. Cases of puerperal convulsions, with remarks. Guy's Hosp Rep 1843; 1 (2nd ser.): 495-517.
3. Rayer P. Traité des Maladies des Reins et des Altérations Sécrétion Urinaire (3 vols.). JB Baillié re: Paris, 1839-1841.
4. Cook H, Briggs J. Clinical observations on blood pressure. Johns Hopkins Hosp Rep 1903; 11: 451-455.
5. Cope I. Plasma and blood volume changes in pregnancies complicated by pre-eclampsia. J Obstet Gynaecol Br Commonw 1961; 68: 413-416.
6. MacGillivray I, Rose GA, Rowe B. Blood pressure survey in pregnancy. Clin Sci 1969; 37: 395-407.
7. Visser W, Wallenburg HC. Maternal and perinatal outcome of temporizing management in 254 consecutive patients with severe pre-eclampsia remote from term. Eur J Obstet Gynecol Reprod Biol 1995; 63: 147-154.
8. Redman CW. Maternal plasma volume and disorders of pregnancy. Br Med J (Clin Res Ed) 1984; 288: 955-956.
9. Brown MA, Zammit VC, Mitar DA et al. Renin-aldosterone relationships in pregnancy-induced hypertension. Am J Hypertens 1992; 5: 366-371.
10. Blumenfeld JD, Laragh JH. Management of hypertensive crises: the scientific basis for treatment decisions. Am J Hypertens 2001; 14: 1154-1167.
11. Gant NF, Daley GL, Chand S et al. A study of angiotensin II pressor response throughout primigravid pregnancy. J Clin Invest 1973; 52: 2682-2689.
12. Zhou CC, Zhang Y, Irani RA et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med 2008; 14: 855-862.
13. Hurault de Ligny BH, Ryckelynck JP, Mintz P et al. Captopril therapy in preeclampsia. Nephron 1987; 46: 329-330.
14. Coen G, Cugini P, Gerlini G et al. Successful treatment of long-lasting severe hypertension with captopril during a twin pregnancy. Nephron 1985; 40: 498-500.
15. Cross JC, Werb Z, Fisher SJ. Implantation and the placenta: key pieces of the development puzzle. Science 1994; 266: 1508-1518.
16. Zhou Y, Fisher SJ, Janatpour M et al. Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for successful endovascular invasion? J Clin Invest 1997; 99: 2139-2151.
17. Jauniaux E, Hempstock J, Greenwold N et al. Trophoblastic oxidative stress in relation to temporal and regional differences in maternal placental blood flow in normal and abnormal early pregnancies. Am J Pathol 2003; 162: 115-125.
18. Karimu AL, Burton GJ. The effects of maternal vascular pressure on the dimensions of the placental capillaries. Br J Obstet Gynaecol 1994; 101: 57-63.
19. Meekins JW, Pijnenborg R, Hanssens M et al. A study of placental bed spiral arteries and trophoblast invasion in normal and severe preeclamptic pregnancies. Br J Obstet Gynaecol 1994; 101: 669-674.
20. Zeek PM, Assali NS. Vascular changes in the decidua associated with eclamptogenic toxemia of pregnancy. Am J Clin Pathol 1950; 20: 1099-1109.
21. Labarrere CA. Acute atherosis. A histopathological hallmark of immune aggression? Placenta 1988; 9: 95-108.
22. Sugimoto T, Kanasaki K, Morita Y et al. Lupus vasculopathy combined with renal infarction: unusual manifestation of lupus nephritis. Intern Med 2005; 44: 1185-1190.
23. Hustin J, Foidart JM, Lambotte R. Maternal vascular lesions in preeclampsia and intrauterine growth retardation: light microscopy and immunofluorescence. Placenta 1983; 4(Spec No): 489-498.
24. Sebire NJ, Sepulveda W. Correlation of placental pathology with prenatal ultrasound findings. J Clin Pathol 2008; 61: 1276-1284.
25. Sugimoto H, Hamano Y, Charytan D et al. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt1) induces proteinuria. J Biol Chem 2003; 278: 12605-12608.
26. Maynard SE, Min JY, Merchan J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658.
27. Sela S, Itin A, Natanson-Yaron S et al. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ Res 2008; 102: 1566-1574.
28. Levine RJ, Maynard SE, Qian C et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683.
29. Venkatesha S, Toporsian M, Lam C et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006; 12: 642-649.
30. Levine RJ, Lam C, Qian C et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992-1005.
31. Lunell NO, Nylund LE, Lewander R et al. Uteroplacental blood flow in preeclampsia measurements with indium-113m and a computer-linked gamma camera. Clin Exp Hypertens B 1982; 1: 105-117.
32. Genbacev O, Joslin R, Damsky CH et al. Hypoxia alters early gestation human cytotrophoblast differentiation/invasion in vitro and models the placental defects that occur in preeclampsia. J Clin Invest 1996; 97: 540-550.
33. Page EW. The relation between hydatid moles, relative ischemia of the gravid uterus, and the placental origin of eclampsia. Am J Obstet Gynecol 1939; 37: 291-293.
34. Ogden E, Hildebrand GJ, Page EW. Rise of blood pressure during ischemia of the gravid uterus. Proc Soc Exp Biol Med 1940; 43: 49-51.
35. Roberts JM, Lain KY. Recent insights into the pathogenesis of preeclampsia. Placenta 2002; 23: 359-372.
36. Redline RW, Patterson P. Pre-eclampsia is associated with an excess of proliferative immature intermediate trophoblast. Hum Pathol 1995; 26: 594-600.
37. Vuorela-Vepsalainen P, Alfthan H, Orpana A et al. Vascular endothelial growth factor is bound in amniotic fluid and maternal serum. Hum Reprod 1999; 14: 1346-1351.
38. Vuorela P, Helske S, Hornig C et al. Amniotic fluid-soluble vascular endothelial growth factor receptor-1 in preeclampsia. Obstet Gynecol 2000; 95: 353-357.
39. Helske S, Vuorela P, Carpen O et al. Expression of vascular endothelial growth factor receptors 1, 2 and 3 in placentas from normal and complicated pregnancies. Mol Hum Reprod 2001; 7: 205-210.
40. Zhou Y, McMaster M, Woo K et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 2002; 160: 1405-1423.
41. Krauss T, Pauer HU, Augustin HG. Prospective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia. Hypertens Pregnancy 2004; 23: 101-111.
42. Levine RJ, Thadhani R, Qian C et al. Urinary placental growth factor and risk of preeclampsia. JAMA 2005; 293: 77-85.
43. Rajakumar A, Brandon HM, Daftary A et al. Evidence for the functional activity of hypoxia-inducible transcription factors overexpressed in preeclamptic placentae. Placenta 2004; 25: 763-769.
44. Caniggia I, Mostachfi H, Winter J et al. Hypoxia-inducible factor-1 mediates the biological effects of oxygen on human trophoblast differentiation through TGFbeta(3). J Clin Invest 2000; 105: 577-587.
45. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005; 308: 1592-1594.
46. Kanasaki K, Palmsten K, Sugimoto H et al. Deficiency in catechol-Omethyltransferase and 2-methoxyoestradiol is associated with preeclampsia. Nature 2008; 453: 1117-1121.
47. Berg D, Sonsalla R, Kuss E. Concentrations of 2-methoxyoestrogens in human serum measured by a heterologous immunoassay with an 125Ilabelled ligand. Acta Endocrinol (Copenh) 1983; 103: 282-288.
48. Barnea ER, MacLusky NJ, DeCherney AH et al. Catechol-o-methyl transferase activity in the human term placenta. Am J Perinatol 1988; 5: 121-127.
49. Yan J, Chen C, Lei J et al. 2-methoxyestradiol reduces cerebral vasospasm after 48 hours of experimental subarachnoid hemorrhage in rats. Exp Neurol 2006; 202: 348-356.
50. Gui Y, Zheng XL, Zheng J et al. Inhibition of rat aortic smooth muscle contraction by 2-methoxyestradiol. Am J Physiol Heart Circ Physiol 2008; 295: H1935-H1942.
51. Tunbridge EM, Harrison PJ, Weinberger DR. Catechol-omethyltransferase, cognition, and psychosis: Val158Met and beyond. Biol Psychiatry 2006; 60: 141-151.
52. Sata F, Yamada H, Suzuki K et al. Functional maternal catechol-Omethyltransferase polymorphism and fetal growth restriction. Pharmacogenet Genomics 2006; 16: 775-781.
53. Nackley AG, Shabalina SA, Tchivileva IE et al. Human catechol- Omethyltransferase haplotypes modulate protein expression by altering mRNA secondary structure. Science 2006; 314: 1930-1933.
54. Barnea ER, Fakih H, Oelsner G et al. Effect of antihypertensive drugs on catechol-O-methyltransferase and monoamine oxidase activity in human term placental explants. Gynecol Obstet Invest 1986; 21: 124-130.
55. Magee LA, Cham C, Waterman EJ et al. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. Br Med J 2003; 327: 955-960.
56. Eskenazi B, Fenster L, Sidney S et al. Fetal growth retardation in infants of multiparous and nulliparous women with preeclampsia. Am J Obstet Gynecol 1993; 169: 1112-1118.
57. Khong TY, De Wolf F, Robertson WB et al. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986; 93: 1049-1059.
58. Rosenberg TJ, Garbers S, Lipkind H et al. Maternal obesity and diabetes as risk factors for adverse pregnancy outcomes: differences among 4 racial/ ethnic groups. Am J Public Health 2005; 95: 1545-1551.
59. Riss P, Bartl W. Placental function, fetal distress, and the fetal/placental weight ratio in normal and gestotic pregnancies. Int J Biol Res Pregnancy 1982; 3: 10-13.
60. Constancia M, Hemberger M, Hughes J et al. Placental-specific IGF-II is a major modulator of placental and fetal growth. Nature 2002; 417: 945-948.
61. Angiolini E, Fowden A, Coan P et al. Regulation of placental efficiency for nutrient transport by imprinted genes. Placenta 2006; 27(Suppl A): S98-102.